CRP and renal cell carcinoma: Interferon-α is an approved drug in RCC and acts strongly anti-inflammatory by inducing circulating tumor necrosis factor receptor p55 and mediates a rapid and strong C-reactive protein (CRP) decrease by inhibiting TNFα.